Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib-based Regimen for R/R ALL
NCT06034561Phase 2Recruiting
- Sponsor
- Instituto do Câncer do Estado de São Paulo
- Start
- Apr 2024
- Primary completion
- Aug 2028
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib in acute lymphoblastic leukemia (ALL), sponsored by Instituto do Câncer do Estado de São Paulo. Primary endpoint: Complete Response at 30 days. Started Apr 2024; status: recruiting.
02
Drugs
bortezomib
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT06034561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06034561.